Summary by Moomoo AI
Cornerstone Pharmaceuticals announced that it will announce Phase I study data for its innovative antibody-conjugated drug CS5001 at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. CS5001 targets the ROR1 receptor, which has a unique tumor-specific activation mechanism, and is intended for the treatment of late solid tumors and lymphomas. This drug has been granted exclusive worldwide development and commercialization rights by Keystone Pharmaceuticals, except in Korea. CORNERSTONE PHARMACEUTICALS IS A BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIVE TUMOR IMMUNOTHERAPY AND PRECISION THERAPY DRUGS. SINCE ITS INCEPTION IN 2015, IT HAS ESTABLISHED A PRODUCT PIPELINE THAT INCLUDES 12 TUMOR CANDIDATE DRUGS. The Company stresses that investors should exercise caution when buying and selling the Company's shares and should not rely too heavily on forward-looking statements.
